Hookipa Pharma (HOOK) AI Stock Analysis

• Market Cap: $13.87M
• Dividend Yield: N/A
• Average Volume (3M): 15.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: -71.52%
• EPS Growth: 1.45%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,930,789
• 10 Day Avg. Volume: 21,467
• 30 Day Avg. Volume: 15,706
• PEG Ratio: 0.01
• Price to Book (P/B): 0.35
• Price to Sales (P/S): 1.16
• P/FCF Ratio: -0.98
• Enterprise Value/Market Cap: -1.42
• Enterprise Value/Revenue: -1.32
• Enterprise Value/Gross Profit: -1.32
• Enterprise Value/Ebitda: 0.37
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $1.00 ▲(12.36% Upside)
• Action: Upgraded Date: 04/09/26
• Date: Action: Upgraded 04/09/26

Positive Factors

Low leverage / declining debt

Material debt reduction and very low leverage materially lower near-term solvency risk and interest burden. This structural strength increases flexibility to fund R&D, negotiate partnerships, or pursue non-dilutive transactions without heavy fixed financing costs, improving strategic optionality.

Negative Factors

Persistent cash burn

Chronic negative cash flow forces reliance on external funding, asset sales, or partnerships to sustain operations. Even with improvement in 2025, continued burn erodes reserves and elevates dilution and execution risk over the medium term, constraining independent development capacity.

Hookipa Pharma Business Overview & Revenue Model

Company Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101,...

Read more

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101,...

How the Company Makes Money

HOOKIPA Pharma historically generates revenue primarily from collaboration and licensing arrangements rather than product sales. These arrangements typically include (when applicable under the specific contract terms) upfront payments for access t...

Read more

HOOKIPA Pharma historically generates revenue primarily from collaboration and licensing arrangements rather than product sales. These arrangements typically include (when applicable under the specific contract terms) upfront payments for access t...

Hookipa Pharma Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	14.86M	9.70M	43.95M	20.13M	14.25M	18.45M
Gross Profit	14.86M	9.02M	41.19M	16.58M	10.65M	13.81M
EBITDA	-53.86M	-35.89M	-40.85M	-77.34M	-60.40M	-70.13M
Net Income	-56.00M	-13.84M	-43.50M	-81.58M	-64.92M	-75.67M
Balance Sheet
Total Assets	52.71M	41.86M	82.55M	161.34M	170.45M	126.05M
Cash, Cash Equivalents and Short-Term Investments	34.23M	37.42M	39.68M	117.10M	113.44M	65.92M
Total Debt	546.00K	135.00K	875.00K	6.56M	6.50M	10.63M
Total Liabilities	24.02M	9.34M	31.33M	71.48M	67.94M	36.45M
Stockholders Equity	28.68M	32.52M	51.21M	89.86M	102.52M	89.59M
Cash Flow
Free Cash Flow	-45.58M	-11.52M	-77.17M	-61.68M	-25.01M	-78.60M
Operating Cash Flow	-45.53M	-11.50M	-76.98M	-57.52M	-20.00M	-66.02M
Investing Cash Flow	-53.00K	6.81M	-194.00K	-4.16M	-5.02M	-12.58M
Financing Cash Flow	-443.00K	-481.00K	-1.28M	65.67M	72.27M	-235.00K

Hookipa Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOOK, the sentiment is Positive. The current price of 0.89 is below the 20-day moving average (MA) of 1.11, below the 50-day MA of 1.07, and below the 200-day MA of 0.96, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 63.86 is Neutral, neither overbought nor oversold. The STOCH value of 74.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOOK.

Hookipa Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHIO	51 Neutral	$13.82M	-1.29	-107.58%	―	―	85.44%
HOOK	49 Neutral	$13.87M	-0.82	-97.61%	―	-71.52%	1.45%
KZIA	48 Neutral	$138.98M	-0.65	-116.86%	―	-98.25%	76.83%
PHGE	42 Neutral	$7.26M	-3.61	-154.50%	―	―	59.90%
WINT	39 Underperform	$842.72K	―	-1302.82%	―	―	99.09%